Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial

References

• Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. The Lancet. 2022;400(10354):769–786. doi:10.1016/S0140-6736(22)01052-2
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi:10.1164/rccm.202202-0399ST
   PubMed Web of Science ®Google Scholar
• Bast A, Weseler AR, Haenen GR, den Hartog GJ. Oxidative stress and antioxidants in interstitial lung disease. Curr Opin Pulm Med. 2010;16(5):516–520. doi:10.1097/MCP.0b013e32833c645d
   PubMed Web of Science ®Google Scholar
• Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med. 1998;92(4):609–623. doi:10.1016/S0954-6111(98)90506-6
   PubMed Web of Science ®Google Scholar
• Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156(6):1897–1901. doi:10.1164/ajrccm.156.6.9706065
   PubMed Web of Science ®Google Scholar
• Muramatsu Y, Sugino K, Ishida F, et al. Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig. 2016;54(3):170–178. doi:10.1016/j.resinv.2015.11.004
   PubMedGoogle Scholar
• Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–2242. doi:10.1056/NEJMoa042976
   PubMed Web of Science ®Google Scholar
• Homma S, Azuma A, Taniguchi H, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17(3):467–477. doi:10.1111/j.1440-1843.2012.02132.x
   PubMed Web of Science ®Google Scholar
• Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax. 1994;49(7):670. doi:10.1136/thx.49.7.670
   PubMed Web of Science ®Google Scholar
• Cotgreave IA, Eklund A, Larsson K, Moldéus PW. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis. 1987;70(2):73–77.
   PubMedGoogle Scholar
• Sakamoto S, Kataoka K, Kondoh Y, et al. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J. 2021;57(1):2000348. doi:10.1183/13993003.00348-2020
   PubMed Web of Science ®Google Scholar
• Martinez FJ, de Andrade JA, Anstrom KJ, King TJ, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–2101.
   PubMed Web of Science ®Google Scholar
• Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13(6):688–694. doi:10.1038/nm1577
   PubMed Web of Science ®Google Scholar
• Yang M, Dong Y, He Q, et al. Hydrogen: a Novel Option in Human Disease Treatment. Oxid Med Cell Longev. 2020;2020:8384742. doi:10.1155/2020/8384742
   PubMed Web of Science ®Google Scholar
• Zhu Q, Wu Y, Li Y, et al. Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. Sci Rep. 2018;8(1):8051. doi:10.1038/s41598-018-26388-3
   PubMedGoogle Scholar
• Gao L, Jiang D, Geng J, Dong R, Dai H. Hydrogen inhalation attenuated bleomycin-induced pulmonary fibrosis by inhibiting transforming growth factor-β1 and relevant oxidative stress and epithelial-to-mesenchymal transition. Exp Physiol. 2019;104(12):1942–1951. doi:10.1113/EP088028
   PubMed Web of Science ®Google Scholar
• Dong WW, Zhang YQ, Zhu XY, et al. Protective Effects of Hydrogen-Rich Saline Against Lipopolysaccharide-Induced Alveolar Epithelial-to-Mesenchymal Transition and Pulmonary Fibrosis. Med Sci Monit. 2017;23:2357–2364. doi:10.12659/MSM.900452
   PubMed Web of Science ®Google Scholar
• Aokage T, Seya M, Hirayama T, et al. The effects of inhaling hydrogen gas on macrophage polarization, fibrosis, and lung function in mice with bleomycin-induced lung injury. BMC Pulm Med. 2021;21(1):339. doi:10.1186/s12890-021-01712-2
   PubMed Web of Science ®Google Scholar
• Terasaki Y, Terasaki M, Kanazawa S, et al. Effect of H(2) treatment in a mouse model of rheumatoid arthritis-associated interstitial lung disease. J Cell Mol Med. 2019;23(10):7043–7053. doi:10.1111/jcmm.14603
   PubMed Web of Science ®Google Scholar
• Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691. doi:10.7326/0003-4819-156-10-201205150-00004
   PubMed Web of Science ®Google Scholar
• Baratella E, Ruaro B, Giudici F, et al. Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis. Diagnostics. 2021;11(5):56.
   Web of Science ®Google Scholar
• Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–969. doi:10.1164/rccm.2111053
   PubMed Web of Science ®Google Scholar
• Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 1997;40(7):1229–1236. doi:10.1002/1529-0131(199707)40:7<1229::AID-ART6>3.0.CO;2-W
   PubMedGoogle Scholar
• Wells AU, King AD, Rubens MB, et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 1997;155(4):1367–1375. doi:10.1164/ajrccm.155.4.9105081
   PubMed Web of Science ®Google Scholar
• Xaubet A, Agustí C, Luburich P, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(2):431–436. doi:10.1164/ajrccm.158.2.9709008
   PubMed Web of Science ®Google Scholar
• Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488–493. doi:10.1164/rccm.200412-1756OC
   PubMed Web of Science ®Google Scholar
• Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639–644. doi:10.1164/rccm.200403-331OC
   PubMed Web of Science ®Google Scholar
• Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001;164(1):103–108. doi:10.1164/ajrccm.164.1.2007077
   PubMed Web of Science ®Google Scholar
• Fu Z, Zhang J. Molecular hydrogen is a promising therapeutic agent for pulmonary disease. J Zhejiang Univ Sci B. 2022;23(2):102–122. doi:10.1631/jzus.B2100420
   PubMed Web of Science ®Google Scholar
• Ichihara G, Katsumata Y, Moriyama H, et al. Pharmacokinetics of hydrogen after ingesting a hydrogen-rich solution: a study in pigs. Heliyon. 2021;7(11):e08359. doi:10.1016/j.heliyon.2021.e08359
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Kaneko E, Sugimoto T, et al. A mitochondrial thioredoxin-sensitive mechanism regulates TGF-β-mediated gene expression associated with epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2014;443(3):821–827. doi:10.1016/j.bbrc.2013.12.050
   PubMed Web of Science ®Google Scholar
• Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15(9):1077–1081. doi:10.1038/nm.2005
   PubMed Web of Science ®Google Scholar
• Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–L534. doi:10.1152/ajplung.00163.2007
   PubMed Web of Science ®Google Scholar
• Domvri K, Organtzis I, Apostolopoulos A, et al. Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression. J Pers Med. 2023;13(9):1307. doi:10.3390/jpm13091307
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Liu YJ, Mao YF, et al. Resveratrol ameliorates lipopolysaccharide-induced epithelial mesenchymal transition and pulmonary fibrosis through suppression of oxidative stress and transforming growth factor-β1 signaling. Clin Nutr. 2015;34(4):752–760. doi:10.1016/j.clnu.2014.08.014
   PubMed Web of Science ®Google Scholar